arrow
M

Marc Ychou

Universite de Montpellier
H指数:72
被引数:3.5万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Regorafenib plus modified gemcitabine-oxaliplatin in patients with advanced biliary tract cancer. The randomized phase Ib/II BREGO study

瑞戈非尼联合改良吉西他滨-奥沙利铂方案治疗晚期胆道癌。BREGO研究(随机 Ib/II 期)。

2025-06-010
OAAI
Post-surgery sequelae unrelated to disease progression and chemotherapy revealed in follow-up of patients with stage III colon cancer

III期结肠癌患者随访中发现与疾病进展和化疗无关的术后后遗症

2024-10-010
OAAI
Triplet chemotherapy plus cetuximab as first-line treatment in extended RAS wild-type metastatic colorectal cancer patients

三联化疗加西妥昔单抗作为延长RAS野生型转移性结直肠癌患者的一线治疗

2024-08-011
OAAI
Post-surgery sequelae unrelated to disease progression and chemotherapy revealed in follow-up of stage III colon cancer patients
2024-03-220
PRE
Stereotactic MR-Guided Radiotherapy for Liver Metastases: First Results of the Montpellier Prospective Registry Study
2023-02-026
OAAI
Disease-free survival as surrogate for overall survival in neoadjuvant chemo(radio)therapy treatment of esophageal or gastro-esophageal junction carcinoma: An analysis of 4518 individual patients and 22 trials
2022-06-010
OA
Stereotactic MR-Guided Radiotherapy for Pancreatic Tumors: Dosimetric Benefit of Adaptation and First Clinical Results in a Prospective Registry Study
2022-03-0927
OAAI
Chemotherapy (doublet or triplet) plus targeted therapy by RAS status as conversion therapy in colorectal cancer patients with initially unresectable liver-only metastases. The UNICANCER PRODIGE-14 randomised clinical trial
2022-01-0622
OA
Unicancer PRODIGE 24/CCTG PA6 trial: Updated results of a multicenter international randomized phase III trial of adjuvant mFOLFIRINOX (mFFX) versus gemcitabine (gem) in patients (pts) with resected pancreatic ductal adenocarcinomas (PDAC)
2021-09-0112
OAAI
Delayed care for patients with newly diagnosed cancer due to COVID-19 and estimated impact on cancer mortality in France
2021-06-0153
OAAI
Sorafenib Plus Irinotecan Combination in Patients With RAS-mutated Metastatic Colorectal Cancer Refractory To Standard Combined Chemotherapies: A Multicenter, Randomized Phase 2 Trial (NEXIRI-2/PRODIGE 27)
2020-12-0112
OAAI
PhaseIIstudy evaluating the association of gemcitabine, trastuzumab and erlotinib as first-line treatment in patients with metastatic pancreatic adenocarcinoma (GATE1)
2020-09-0227
OAAI